Logo

MCTA

Charming Medical Limited Class A Ordinary Shares

MCTA

Charming Medical Limited Class A Ordinary Shares • NASDAQ
$29.36 ▲ 6.75% (+1.85)
Market Cap $449.85 M
52w High $31.70
52w Low $4.30
Dividend Yield 0%
P/E 419.36
Volume 4.25M
Outstanding Shares 15.32M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $2.761M ▲ $5.356M ▼ $5.306M ▼ $49.243K ▲
Q2-2024 $2.692M ▲ $5.375M ▲ $6.056M ▲ $-681.055K ▲
Q4-2023 $2.104M $4.882M $6.028M $-1.079M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow

Five-Year Company Overview

Income Statement

Income Statement The income statement shows a company that is still very small in scale, with only modest revenue and essentially break-even performance over the last few years. Reported profits per share have recently turned positive, but on such a small business base that they do not yet signal a proven, durable earnings model. Overall, the financial history looks thin, early-stage, and not yet tested through tougher business conditions.

Balance Sheet

Balance Sheet The balance sheet appears very light, with limited assets, little or no reported cash, and no meaningful debt. This suggests the company is not heavily leveraged, which is a plus, but it also seems to lack a strong financial cushion if the business encounters stress. Equity is also thin, which means there is not much buffer to absorb surprises, and future growth may depend heavily on raising outside capital rather than funding expansion from internal resources.

Cash Flow

Cash Flow Reported cash flows are essentially flat and do not yet tell a clear story about the company’s ability to generate cash from its operations. This is typical of a very small or early-stage business but makes it hard to judge the sustainability of its model. Until there is a longer record of consistent positive operating cash flow, the company’s true financial strength and self-funding capacity remain uncertain.

Competitive Edge

Competitive Edge Charming Medical competes in a crowded wellness and beauty market but tries to stand out by focusing on Traditional Chinese Medicine–inspired services for women’s health. Its niche positioning, use of certified practitioners, and “Beauty Lab” brand give it some differentiation and a clear target audience. The franchise approach could help expansion, but the underlying services are not impossible for rivals to copy, so the long-term strength of its moat is still unproven. On top of that, the SEC trading suspension and investigation into potential market manipulation introduce a serious trust and reputational challenge that may weigh on its competitive standing, especially with international stakeholders.

Innovation and R&D

Innovation and R&D The company’s main innovation is blending traditional Chinese therapies with modern aesthetic technology and branding these as specialized treatments and products. Some offerings, like needle-free thread embedding and eye-care therapies, sound differentiated, but publicly available details on what is truly proprietary are limited. Management has indicated plans to use IPO proceeds for research into herbal products and new technologies, which, if executed well, could deepen its moat. For now, the R&D story is more about future intentions than a visible, established pipeline of unique, defensible innovations.

Summary

Overall, Charming Medical looks like a very small, niche healthcare and wellness business with a short and limited financial track record. The core concept—TCM-inspired women’s health and beauty services supported by branded products and training—offers an interesting positioning, but the business has not yet demonstrated scaled, reliable profitability or strong cash generation. Its balance sheet and cash flow profile suggest only modest financial resilience, making it sensitive to business setbacks and reliant on external funding for growth. The most important overhang is non-financial: the SEC trading suspension and investigation into potential market manipulation, which creates significant uncertainty about the company’s path forward. How the regulatory issues are resolved, along with evidence of real, repeatable operating performance, will be key to understanding whether the early promise of the model can translate into a stable, durable enterprise.

NEWS

October 28, 2025 · 4:15 PM UTC

Charming Medical Limited Announces Full Exercise of Representative's Over-allotment Option

Read more

October 22, 2025 · 12:51 PM UTC

Charming Medical Limited Announces Closing of Initial Public Offering

Read more

October 21, 2025 · 11:00 AM UTC

Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq

Read more